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ABSTRACT
Introduction: The objective of this study was to
evaluate real-world treatment patterns of type 2
diabetes (T2D) patients initiating glucagon-like
peptide-1 receptor agonists (GLP-1 RAs) in
Germany (GE), the United Kingdom (UK),
France (FR), the Netherlands (NE), Belgium
(BE), and Sweden (SE).
Methods: Adult T2D patients initiating
exenatide twice daily (exBID), liraglutide once
daily (LIRA) or exenatide once weekly (exQW)
were identified using the IMS LifeLinkTM (IMS
Health, Danbury, CT, USA): Electronic Medical
Records (EMR; GE/UK/FR) and IMS LifeLinkTM:
longitudinal prescriptions (LRx; NE/BE/GE/UK)
databases, and national health register data (SE),
between 2010 and 2012. Therapy initiation date
was termed ‘index date’. Eligible patients had
C180-day pre- and variable follow-up
(minimum C360-day post-index exBID and
LIRA, C180-day post-index exQW). Treatment
modification and persistence were evaluated
over 180 days. Kaplan–Meier (KM) survival
curves and Cox proportional hazards models
(PHMs; EMR databases only) evaluated stopping
of the index therapy (measured as first of
discontinuation or switch).
Results: 30,206 exBID, 5,401 exQW, and
52,155 LIRA patients were included in the
analysis (46.0–66.9% male; mean age range
55.4–59.3 years). Mean follow-up was
20.3–27.4 months for exBID and LIRA, and
7.6–13.9 months for exQW. Across the
databases, the proportion experiencing a
treatment modification at 180 days was
highest among exBID (37.6–81.7%) compared
to LIRA (36.8–56.6%) and exQW (32.3–47.7%).
The proportion persistent at 180 days was
lowest among exBID patients (46.8–73.5%)
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compared to LIRA (50.6–80.1%) or exQW
(57.5–74.6%). In the KM analyses, LIRA
patients had a lower proportion stopping
therapy at all time points compared to exBID
patients, across the databases. In the Cox PHMs,
LIRA was associated with a significantly lower
risk of stopping compared to exBID; in GE,
exQW was associated with a lower risk
compared to exBID and LIRA.
Conclusion: Treatment patterns varied among
GLP-1 RA patients, with persistence highest
among either LIRA or exQW across countries,
and lowest among exBID. Longer-term data
would be useful, particularly given limited
exQW follow-up due to more recent launch.
Keywords: Databases; Diabetes mellitus;
Exenatide BID; Exenatide QW; Glucagon-like
peptide 1; Liraglutide; Retrospective studies;
Treatment outcome; Type 2/drug therapy
INTRODUCTION
The International Diabetes Federation estimates
that there are 56.3 million adults with diabetes,
representing 8.5% of European adults [1]. Type
2 diabetes (T2D) constitutes 85–95% of all
diabetes, and the incidence/prevalence
continues to increase due in part to obesity,
physical inactivity, and poor diet. This has
substantial cost implications to healthcare
systems and society [1]. Upon diagnosis of
T2D, patients are often required to engage in
healthy eating, weight control, and increased
physical activity to improve glycemic
sensitivity/control [2]. However, most patients
will require drug therapy, with metformin
monotherapy generally preferred as initial
pharmacological treatment. Over time,
combination therapy is needed, with the
American Diabetes Association (ADA)/
European Association for the Study of Diabetes
(EASD) recommending one of five treatment
classes combined with metformin: a
sulfonylurea, thiazolidinediones (TZD),
dipeptidyl peptidase-4 (DPP-4) inhibitor, basal
insulin or a glucagon-like peptide-1 receptor
agonist (GLP-1 RA) [2].
GLP-1 RAs mimic endogenous GLP-1,
stimulating insulin release from the pancreas
and suppressing glucagon secretion [2]. GLP-1
RAs are associated with high glycemic efficacy,
weight loss and low risk of hypoglycemia, but
with some risk of gastrointestinal side effects.
While concerns of an association with
pancreatic disease exist, the US Food and Drug
Administration (FDA) and European Medicines
Agency (EMA) have agreed that a causal
association is inconsistent with the current
data [3]. There are five EMA approved GLP-1
RAs: exenatide twice daily (exBID; Byetta,
AstraZeneca; approved in 2006), liraglutide
once daily (LIRA; QD; Victoza, Novo Nordisk;
approved in 2009), exenatide once weekly
(exQW; Bydureon, AstraZeneca; approved in
2011), lixisenatide once daily (Lyxumia,
Sanofi; approved in 2013), and albiglutide
once weekly (EperzanTM, GlaxoSmithKline;
approved in 2014). In addition, the
Committee for Medicinal Products for Human
Use (CHMP) has recently adopted a positive
opinion and recommended the granting of a
marketing authorization for dulaglutide once
weekly (TrulicityTM, Eli Lilly).
Daily doses, injection frequencies and
injection time related to meals of current GLP-
1 RA therapies are variable. For example, the
initial dose of exBID is 5 lg injected under the
skin (subcutaneously) twice daily, 60 min
before two major meals with at least 6 h in
between. The dose can be increased to 10 lg
twice daily after 1 month of therapy [4]. LIRA is
administered once daily independent of meals
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and should be initiated with a dose of 0.6 mg
once daily for the first week, followed by a dose
increase to 1.2 mg once daily [5]. If the 1.2 mg
dose does not result in acceptable glycemic
control, the dose may be increased to 1.8 mg
after at least 1 week, although the EMA [6] and
the National Institute for Health and Care
Excellence (NICE) [7] state that the available
evidence suggests only marginal benefit of this
escalation on glycemic control. ExQW is
administered once per week independent of
meals at a dose of 2.0 mg [8]. While the ADA/
EASD recommend GLP-1 RA therapy in second-
or third-line therapy [2], some European Union
(EU) health care authorities, including the
United Kingdom (UK) [7], the Netherlands
(NE) [9], Sweden (SE) [10], and Belgium (BE)
[11], generally recommend GLP-1 RAs as a
third-line therapy, often restricted to certain
populations (obese, intolerant to other
therapies, etc.).
Only a few studies have compared treatment
patterns or variable dosing between exBID and
LIRA [12–14]. Little is known about treatment
patterns among GLP-1 RA therapy users in the
real-world setting, particularly for exQW, or
average patient dosing given variability in
dosing for exBID and LIRA. The primary
objective of this analysis was to evaluate
treatment patterns among T2D GLP-1 RA
therapy initiators, specifically persistence with
the index therapy and treatment modification
[discontinuation, switch, stop (a composite
outcome of either discontinuation or switch)
or augmentation]. Secondary objectives
included evaluating average daily dose (ADD)
of the therapy and the patient characteristics
associated with risk of stopping therapy. These
outcomes were evaluated using available
databases containing prescription data in
Germany (GE), the UK, France (FR), NE, BE,
and SE. When this study was conducted, exBID,
exQW, and LIRA were the only approved GLP-1
RAs; therefore, these therapies comprise the
cohorts of this study.
METHODS
A retrospective cohort analysis was conducted
using eight databases in six European countries
(GE, the UK, FR, NE, BE, and SE). This study
involved a retrospective cohort analysis using
eight databases, and the analysis does not
contain studies with human or animal subjects
performed by any of the authors. Research
ethics approval was received from the regional
Ethics Review Board in Stockholm in order to
conduct the Swedish analysis. Ethics approval
was not required in the other countries.
Data Sources
Electronic Medical Records
The IMS LifeLinkTM (IMS Health, Danbury, CT,
USA): Electronic Medical Records databases
(henceforth referred to as EMR) were used in
GE, the UK, and FR. EMR contains longitudinal
anonymized patient-level data from the EMRs
of office-based physician practices [general
practitioners (GPs) in the UK/FR, GPs/
diabetologists in GE]. Data include basic
demographics, physician-recorded medical
diagnoses [International Statistical
Classification of Diseases (ICD) ICD-10 format]
and written prescriptions [EphMRA Anatomical
Classification (ATC) code]. EMR covers
approximately 18.9%, 6.7%, and 7.6% of the
GE, UK, and FR populations, respectively.
Retail Pharmacy
The IMS LifeLinkTM: Longitudinal Prescriptions
databases (henceforth referred to as LRx) were
used in the NE, BE, the UK (GPs only; limited to
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aggregated data analysis due to privacy
legislation), and GE. LRx contains prescription
data (EphMRA ATC code) and limited
demographic data [e.g., age (unavailable in BE;
age bands only in the UK), gender]. The
representativeness of the databases based upon
current population and pharmacy coverage in
2013 is: 72% NE, 32% BE, 51% GE, and 44% UK.
Both EMR and LRx databases were utilized in
GE and UK as they provide somewhat different
samples: physician-recorded pharmacy and
clinical data vs. filled pharmacy prescription
data. Overlap in the populations from the two
databases is possible.
Sweden
The Swedish national drug register was utilized,
which provides national, patient-level data on
all prescription drugs dispensed at all
pharmacies from the Swedish National
Pharmacy Corporation (World Health
Organization [WHO] ATC code). In addition,
the Swedish Mortality Register was used to
identify patient death and provide full
visibility into patient follow-up. Research
ethics approval was received from the regional
Ethics Review Board in Stockholm.
Patient Selection
Patients were first identified based on a
prescription for the therapy of interest (exBID,
exQW, or LIRA) within the selection window
(Table 1), which varied by country and was
adjusted for exQW given its more recent launch
(June 2011). The first prescription for a therapy
of interest within the selection window was
termed the ‘index therapy’ and the date was
termed the ‘index date’. Patients were followed
through the end of continuous eligibility (CE;
i.e., visibility) or study end date, whichever
occurred first.
Adult patients (C18 years on the index date)
were identified as eligible if they met the
following inclusion/exclusion criteria: (1)
evidence of T2D [no evidence of type 1
diabetes (T1D); see Table 1 for database-specific
criteria], (2) C180-day CE pre-index, (3) C360-
day CE post-index (C180-day post-index for
exQW patients only) within the database (see
Table 1 for database-specific CE criteria), (4)
naı¨ve to the initiated therapy class with no
prescription for any GLP-1 RA (EphMRA ATC
A10S0; WHO ATC A10BX04/A10BX07) in the
180-day pre-index period, (5) not initiating any
other injectable antihyperglycemic therapy
(GLP-1 RA or insulin) on the index date other
than the index therapy; and (6) non-missing
age or gender required (age unavailable in BE
LRx).
Measures and Analysis
Baseline demographic (age and gender where
available) characteristics were assessed as well as
non-index antihyperglycemic therapy classes
used in the pre-index period and concomitant
use on the index date. A non-index
antihyperglycemic therapy class was defined as
concomitant if the time between a prescription for
a therapy class in the pre- and post-index was
B120 days, with overlap on the index date, or if
the therapy class was prescribed/filled on the
index date. Additional EMR clinical
characteristics were summarized where available,
including body mass index (BMI), comorbidities
in the pre-index and physician type (GP/
diabetologist in GE). Patients with missing
prescription quantity data were excluded from
the subsequent ADD and treatment modification
analyses in FR EMR (35.8% exBID, 52.6% LIRA)
and NE LRx (0.6% exBID; 3.7% exQW, 0.5%
LIRA). There was no missing prescription quantity
data for the other databases.



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Diabetes Ther (2014) 5:499–520 503
Experience of a first treatment modification
was assessed during the 180-day post-index
period. Treatment modifications included
discontinuation, switch, augmentation, off-
label up-titration and down-titration, assessed
following previously published methods [13].
Titration was calculated using ADD given the
lack of a reliable prescribed dose field.
Discontinuation was defined as a gap in a
series of successive index therapy prescriptions
C29 the expected duration of the first
prescription. Switching was defined as a new
non-index antihyperglycemic prescription (new
antihyperglycemic therapy class not observed in
the pre-index or index date, or non-index
antihyperglycemic therapy from the same
class) within 30 days before or after
discontinuation of the patient’s index
treatment. Augmentation was defined as C2
prescriptions for a new non-index
antihyperglycemic prescription, started more
than 30 days before the end of follow-up or
the index discontinuation date. Off-label up-
titration was identified as any dose increase
outside of label recommendations (daily dose
[20 lg for exBID; two consecutive prescriptions
with daily dose [1.8 mg for LIRA). Down-
titration was defined as two consecutive
prescriptions with doses lower than the index
dose. Persistence (i.e., continuation of the index
therapy) was evaluated during the 180-day post-
index period. Patients were considered
persistent until evidence of discontinuation or
switch. A stop outcome was defined as the
occurrence of either discontinuation or switch
(whichever came first).
Index therapy ADD was assessed for all
patients while persistent (until discontinuation
or switch); patients who augmented their index
therapy continued to factor into that index
therapy’s ADD. ADD was calculated by dividing
the total amount or units of drug prescribed by
the number of days between two consecutive
prescriptions. ADD was evaluated by calendar
month intervals for patients with an index
therapy prescription within that month.
Average ADDs over calendar months were
summarized to provide both a yearly and
overall ADD. An average weekly dose (AWD)
was calculated for exQW by multiplying the
ADD by 7. Prescriptions received within 14 days
of a previous prescription were excluded to
avoid overestimating ADD due to duplicate
prescriptions or ambiguous up-titration with
an exception for the prescription following the
index therapy (i.e., the second prescription) if
the gap between the second and third
prescription was equal to the expected
duration of the prescribed therapy. ADD in the
UK LRx (aggregated data) was calculated as
follows: total units of drug prescribed in a
month were summed and divided by the total
number of patients with a prescription in that
month; then divided by the number of days in
that month. This does not account for multiple
prescriptions prescribed for a patient in a
month which could result in over-inflation of
ADD estimates. For yearly and overall ADD/
AWD calculations, calendar months with less
than 30 patients were trimmed.
A wide range of ADDs were expected, due to
variability in gaps between consecutive
prescriptions [13]. Given overall ADD
sensitivity to small gaps/overlaps in available
prescriptions, we grouped ranges of ADD values
in categories consistent with labeled use and
dispensed doses to calculate titration outcomes.
For exBID: calculated ADD 5–15 lg = 10 lg;
calculated ADD [15–25 lg = 20 lg; and
calculated ADD [25 lg = dose above label; for
LIRA: calculated ADD 0.6–1.5 mg = 1.2 mg;
calculated ADD [1.5–2.1 mg = 1.8 mg; and
calculated ADD [2.1 mg = dose above label.
On-label up-titration was assessed as a separate
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outcome, defined as any dose increase based on
label recommendations (two consecutive
prescriptions with ADD of 20 lg for exBID;
two consecutive prescriptions with ADD
C1.2 mg up to 1.8 mg for LIRA).
Descriptive summary statistics were used to
describe frequency and percentage distributions
for categorical variables while continuous
variables were described using the mean/
standard deviation/median. Time to stop of
the index therapy over the variable follow-up
was assessed using Kaplan–Meier (KM) analysis.
For the EMR cohorts, Cox proportional hazards
models (PHMs) were developed to assess risk of
stopping the index therapy. Statistical and
descriptive analyses were performed using SAS
version 9.1 (SAS Institute Inc., Cary, NC, USA).




After application of the inclusion/exclusion
criteria, the final sample consisted of 30,206
exBID patients (300 GE EMR/388 UK EMR/120
FR EMR/171 NE LRx/845 BE LRx/23,809 UK
LRx/4,230 GE LRx/343 SE), 5,401 exQW
patients (174 GE EMR/270 NE LRx/3,207 UK
LRx/1,629 GE LRx/121 SE), and 52,155 LIRA
patients (906 GE EMR/306 UK EMR/399 FR
EMR/2,189 NE LRx/1,384 BE LRx/30,436 UK
LRx/12,727 GE LRx/3,808 SE). Because
individual patient prescription data were
unavailable from the UK LRx due to privacy
legislation, it was not possible to evaluate
clinical characteristics or treatment patterns;
the aggregate UK LRx data allowed only for the
aggregate analysis of ADD outcomes.
Demographic and clinical characteristics of
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age at index ranged from 55.4 to 59.3 years old
for patients across index therapy cohort and
database, and approximately half or more were
male (46.0–66.9%). ExBID and LIRA patients
had approximately 2 years of follow-up; exQW
patients had shorter follow-up ranging from 7.6
to 13.9 months. Available demographic
characteristics for the UK LRx sample were
limited (due to privacy legislation) to age at
index prescription [most often between 50 and
64 years (48.2–49.0%)] and gender with over
half male (52.7–55.4%) across therapy cohorts.
On average, patients had 1.6–2.3
antihyperglycemic therapy classes in the
180-day pre-index (with a median of 2 classes
for most index therapy cohorts), and patients
most often used a median of 1 concomitant
antihyperglycemic therapy class during index.
Biguanides, followed by sulfonylureas were the
most common antihyperglycemic therapy
classes used in both the 180-day pre-index and
concomitant with the index therapy, while
insulin use was less frequent.
For EMR, data on BMI were available for
most patients only in the UK, where the
majority of exBID and LIRA patients had a
BMI indicative of obesity (BMI C 30.0) at index
(76.8% and 67.0%), although only 12.1% and
10.5% were diagnosed with obesity,
respectively. Cardiovascular (CV) disease was
the most common comorbidity of interest
observed in the 180-day pre-index (range
53.7–63.7%) in GE and UK across cohorts
(diagnoses were less frequently recorded in FR).
Treatment Patterns
Across databases, the proportion of patients
persistent at 180 days was higher among LIRA
and exQW patients compared to exBID
(Table 3), and for LIRA patients ranged from
50.6% to 80.1% (GE EMR and GE LRx), for
exBID patients ranged from 46.8% to 73.5% (FR
EMR and NE LRx), and for exQW patients
ranged from 57.5% to 74.6% (GE LRx and NE
LRx). The proportion persistent at 180 days was
highest for exQW in GE EMR, and second to
LIRA in NE LRx, GE LRx and SE.
KM results for time to stop (discontinuation
or switch) over the variable follow-up by index
therapy cohort (excluding the UK LRx) can be
found in Fig. 1a–c. Median time to stop for
exBID ranged from 95 days to 275 days (GE EMR
and NE LRx); 265 days to 377 days for exQW
(GE LRx and GE EMR; note: fewer than 50%
experienced stop in NE LRx or SE), and 179 days
to 814 days for LIRA (GE EMR and GE LRx).
Across databases, the proportion stopping was
lower among LIRA patients compared to exBID
at all time points. Comparisons to exQW are
limited given the shorter follow-up period
(180 days minimum).
Treatment modifications at 180-day post-
index can be found in Table 3 by index
therapy cohort. More exBID patients
experienced treatment modification at
180 days compared to LIRA or exQW patients
in each database. More than half of exBID
patients experienced treatment modification
[ranging from 55.7% to 81.7% (BE LRx and UK
EMR)] with the exception of NE LRx (37.6%).
Approximately, half of LIRA patients
experienced treatment modification ranging
from 46.3% to 56.6% (SE and FR EMR), again
with the exception of NE LRx (36.8%). The
proportion experiencing treatment
modification at 180 days among exQW ranged
from 32.3% to 47.7% (NE LRx and GE LRx);
fewer exQW patients experienced treatment
modification compared to LIRA patients in GE
EMR (40.8% and 56.2%) and SE (39.7% and
46.3%), while proportions were more similar in
NE and GE LRx. Discontinuation was the most
common first treatment modification type
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across index therapies for all countries with the
exception of LIRA patients in GE LRx where
down-titration was most common.
Cox Proportional Hazards Models for Risk
of Stopping
Type of index therapy was significantly
associated with risk of stopping in all EMR
countries, with LIRA associated with a lower risk
of stopping compared to exBID (Table 4). In GE,
compared to exBID, exQW was associated with
a 54% lower risk while LIRA was associated with
a 31% lower risk (both P\0.001). In UK,
compared to exBID, LIRA was associated with
a 28% lower risk (P\0.001). In FR, compared to
exBID, LIRA was associated with a 38% lower
risk (P = 0.002). In both GE and UK,
concomitant use of a biguanide was associated
with a lower risk of stopping the index therapy
compared to no biguanide use. In GE, other
significant predictors for stop included male
gender, GP physician type, depression and non-
neuropathic pain in the pre-index and no CV
disease and concomitant insulin use. It is
important to note the availability of physician
type in GE only and the different sample sizes,
which may impact model findings.
Average Daily Dose
ADD by calendar year (year of prescription) and
overall (over the entire follow-up period) is
reported in Table 5. Mean (SD) overall ADD for
exBID was on the higher end of the approved
doses and ranged from 16.39 (1.68) to
19.36 (1.04) lg (SE and UK EMR); overall ADD
calculated at the aggregate level in UK LRx was
higher: 20.73 (0.58) lg. Overall ADD for LIRA
was generally in the middle of the indicated
doses and ranged from 1.30 (0.07) to
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Fig. 1 Kaplan–Meier analyses for time to stop: a exBID,
b exQW, c LIRA. Patient-level analysis was not possible
with the UK LRx due to privacy legislation; therefore,
treatment pattern outcomes were not assessed. BE Belgium,
EMR Electronic Medical Records databases, exBID
exenatide twice daily, exQW exenatide once weekly, FR
France, GE Germany, LIRA liraglutide once daily, LRx
Longitudinal Prescriptions databases, NE The Netherlands,
SE Sweden, UK United Kingdom
Diabetes Ther (2014) 5:499–520 513
Table 4 Cox proportional hazards models for risk of stopping in Germany, UK, and France EMR; dependent variable:
experience of stop










Lower limit Upper limit
Index treatment (reference: exBID)
exQW -0.768 0.129 35.678 \0.0001 0.46 0.361 0.597
LIRA –0.379 0.074 25.857 \0.0001 0.69 0.592 0.792
Male (reference: female) 0.155 0.065 5.752 0.017 1.17 1.029 1.326
Physician type (reference: GP)
Diabetologist –0.357 0.083 18.567 \0.0001 0.70 0.595 0.823
Speciﬁc relevant comorbidities (yes vs. no)
CV diseaseq –0.190 0.069 7.618 0.006 0.83 0.723 0.946
Depression 0.254 0.115 4.910 0.027 1.29 1.030 1.615
Pain (non-neuropathic) 0.197 0.098 4.042 0.044 1.22 1.005 1.475
Concomitant antihyperglycemic treatment classes used (yes vs. no)
Insulin 0.542 0.111 24.061 \0.0001 1.72 1.385 2.136
Biguanide –0.163 0.065 6.289 0.012 0.85 0.747 0.965
Other OAM –0.155 0.093 2.741 0.098 0.86 0.713 1.029





Chi square P value Hazard
ratio
95% conﬁdence interval
Lower limit Upper limit
Index treatment (reference: exBID)
LIRA –0.326 0.092 12.440 0.0004 0.72 0.603 0.865
Speciﬁc relevant comorbidities (yes vs. no)
Obesity –0.242 0.143 2.868 0.0903 0.79 0.594 1.039
Concomitant antihyperglycemic treatment classes used (yes vs. no)
Biguanide –0.256 0.108 5.592 0.018 0.77 0.627 0.957





Chi square P value Hazard
ratio
95% conﬁdence interval
Lower limit Upper limit
Index treatment (reference: exBID)
LIRA –0.473 0.151 9.791 0.002 0.62 0.464 0.838
Speciﬁc relevant comorbidities (yes vs. no)
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ADD calculated at the aggregate level in UK LRx
was 1.49 (0.04) mg. Overall AWD (ADD 9 7)
exQW ranged from 2.00 (0.07) to
2.14 (0.18) mg (GE LRx and GE EMR); overall
AWD calculated at the aggregate level in UK
LRx was 2.18 (0.07) mg.
DISCUSSION
Our research suggests that treatment patterns
varied among GLP-1 RA patients. Across the
databases, the proportion of patients that
experienced a treatment modification and that
stopped the index therapy by 180-day post-
index were higher among exBID compared to
LIRA QD or exQW patients. A greater
proportion of exBID patients stopped therapy
than LIRA patients at all time points in the KM
analyses, further supported by the Cox PHMs.
While treatment pattern results for ExQW
varied by dataset relative to LIRA, the Cox
PHM results in GE EMR supported the observed
lower likelihood of stopping for exQW relative
to LIRA and exBID. The exQW data should be
interpreted with caution; comparisons are
restricted given the shorter follow-up due to
more recent launch. While the overall ADDs of
GLP-1 RAs were generally within the indicated
ranges, the overall ADD for LIRA was generally
in the middle of the indicated doses (1.2 or
1.8 mg following the second week); and on
average, higher than the 1.2 mg dosing
recommended by the EMA [6] and NICE [7],
suggesting that on average, many patients are
using and benefitting from the higher dose.
Some differences between treatment patterns by
index therapy were observed between databases
in GE (EMR and LRx), including the proportion
stopping therapy; it is important to consider the
different populations (physician EMR records
vs. filled pharmacy claims) and variable follow-
up periods, as well as the much higher sample
size for LRx. Overall ADD results in GE EMR
compared to GE LRx were similar (exBID: 17.65,
17.70 lg; exQW: 0.31, 0.29 mg; LIRA: 1.44,
1.40 mg, respectively). The ADD was higher as
calculated in the UK LRx for all therapies
compared to the UK EMR, likely related to
over-estimation with the aggregate-level
analysis. It is important to note that the
Table 4 continued





Chi square P value Hazard
ratio
95% conﬁdence interval
Lower limit Upper limit
Depression 0.587 0.353 2.755 0.097 1.80 0.899 3.594
Table presents only borderline signiﬁcant or signiﬁcant predictors, for brevity’s sake
CV Cardiovascular, EMR Electronic Medical Records databases, exBID exenatide twice daily, exQW exenatide once weekly,
GP general practitioner, LIRA liraglutide once daily, OAM Oral antihyperglycemic medication, UK United Kingdom
 Antihyperglycemic therapy deﬁned as concomitant if (1) time between therapy class prescriptions in pre- and post- index
of 120 days or less, with overlap on index or (2) with prescription on the index date
q CV disease included the following ICD-10 (International Classiﬁcation of Diseases) codes: E78.0, E78.2, E78.4–E78.6;
I10; I11.0, I11.9; I15.2, I15.8, I15.9; I20, I20.0, I20.1, I20.8, I20.9; I21, I21.0–I21.4, I21.9; I22.0, I22.1, I22.8, I22.9; I24.0,
I24.8, I24.9; I25.0–I25.6, I25.8, I25.9; I44, I44.0–I44.7; I45.0; I46, I46.0, I46.9; I50, I50.0, I50.1, I50.9; I60, I60.0–I60.9;
I61, I61.0–I60.6, I60.8, I60.9; I61, I61.0–I61.9; I63, I63.0–I63.6, I63.8, I63.9; I64; I70, I70.0–I70.2, I70.8, I70.9; I71,
I71.0–I71.6, I71.8, I71.9; I72, I72.0–I72.4, I72.8, I72.9; I73, I73.8, I73.9; I74, I74.0–I74.5, I74.8, I74.9; I79, I79.2, I79.8;
I82, I82.2, I82.3, I82.8, I82.9
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prescription of GLP-1 RA therapies in the
countries evaluated may be influenced by local
regulation and reimbursement policies, such as
reimbursement in the third-line setting only
among restricted populations [7, 9–11],
prescribing restricted to specialists [15] or even
restrictive prescribing targets for physicians
[16], related to the costs and cost-effectiveness
perceptions of GLP-1 RA therapies which may
vary in each considered country.
The results presented must be viewed in light
of some limitations associated with using
electronic medical record and prescription data.
Patients included in EMR (and their physicians)
and LRx databases may not be fully
representative of all patients in the respective
country, as data are collected only from
physicians who have agreed to participate in
the EMR panel or only from pharmacies which
participate in the database. For EMR, only care
within the EMR practice setting is visible, and
data linkage is not available if a patient visits
multiple physicians within the EMR panel, as the
patient is assigned different identification
numbers by each physician. The prescription
information only highlights prescriptions
written by the participating physician, with no
information on actual pharmacy fills. As
mentioned earlier, the UK and FR data are
limited to GPs. LRx lacks visibility to any
prescriptions purchased outside the pharmacies
included in the database. The lack of medical
diagnosis codes in LRx and SE made it difficult to
confirm the presence/absence of T1D and/or
T2D, however, oral antihyperglycemic
medication (OAM) use in the 180-day pre-
index was required, with the exception of the
UK LRx where no patient-level data are available.
It is possible that the UK LRx patient sample
included non-T2D users, potentially for off-label
weight-loss benefits despite the sole indication
of GLP-1 RAs for T2D. Further, lack of clinical
data limited our ability to adjust for confounding
factors. Both EMR and LRx lack the ability to
identify patient mortality. The SE data provide
more comprehensive insight into treatment
patterns given the national pharmacy data and
identification of patient mortality. No
assumptions can be made about actual filling of
prescriptions (EMR) or consumption of all of the
medication supplied in each prescription on
time. Lastly, our study was subjected to the
same limitations that are often inherent in
retrospective claims-based analyses. Our results
can only establish associations and not cause-
and-effect relationships. Our sample may be
biased towards a healthier population due to
our continuous enrollment requirements, which
were necessary to ensure adequate visibility into
the patients’ clinical history; this may be less of
an issue among patients with chronic diseases,
such as diabetes. Further, small sample sizes for
some cohorts/databases limited comparisons.
Few studies have compared treatment
patterns and ADD between GLP-1 RA
therapies. Miller et al. [13] compared exBID
and LIRA treatment patterns using the GE EMR
database. Patients were identified initiating
therapies of interest between January 2009 and
April 2010 with C90-day post-index follow-up.
Mean ADD was 16.7 lg for exBID and 1.43 mg
for LIRA, while in our GE EMR analysis, we
found a higher ADD for exBID, 17.7 lg, and a
similar ADD for LIRA, 1.44 mg. In addition,
based on Cox PHM estimates in the Miller et al.
[13] study, index therapy was not a statistically
significant predictor of time to treatment
modification. In our model for time to
stopping (discontinuation or switch), LIRA was
associated with a lower risk of stop. Differences
between study results may be partially
explained by different study periods as our
analysis utilized longer-follow-up for LIRA
following its approval in Europe in 2009.
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McDonell et al. [12] examined the real-world
daily usage of exBID and LIRA using UK LRx
between November 2008 and March 2011 in a
similar analysis of ADD using an aggregate
approach. The average daily usage was
estimated at 20.49 lg for exBID and 1.50 mg
for LIRA. We found similar results with an
overall ADD of 20.73 lg for exBID and 1.49 mg
for LIRA. Using LRx in GE, Fuchs et al. [14]
found a mean ADD of 1.29 mg excluding
extreme values and 1.42 mg including extreme
values for LIRA; while the latter is closer to our
observed ADD of 1.44 mg in GE EMR and
1.40 mg in GE LRx, our methods varied
(trimming of extreme values vs. trimming
months with N\30 patients). Additionally,
Fuchs et al. [14] captured an earlier time
period (2009–2010).
CONCLUSIONS
Our study is the first, to our knowledge, to
comprehensively examine treatment patterns
and ADD of GLP-1 RA therapies, including
exQW, across various EU countries and
datasets. In this real-world analysis, ADD was
within indicated label ranges for GLP-1 RA
therapies. Treatment patterns varied among
GLP-1 RA patients in the sample of European
countries considered in this study, with
persistence highest among either LIRA or
exQW across countries, and lowest among
exBID. Longer-term data would be useful to
further elucidate practice patterns associated
with these medicines, particularly exQW.
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